Navigation Links
Cephalon Provides Update on Regulatory Review of NUVIGIL for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
Date:12/21/2009

at has been reported in adults and children taking modafinil, a racemic mixture of S- and R-modafinil (the latter is armodafinil, the active ingredient in NUVIGIL). NUVIGIL is not approved for use in pediatric patients for any indication.

The most common adverse events in controlled clinical trials (five percent or greater) were headache, nausea, dizziness, and insomnia. Full prescribing information for NUVIGIL is available at www.NUVIGIL.com.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of many unique products in four core therapeutic areas: central nervous system, inflammatory diseases, pain and oncology. A member of the Fortune 1000 and the S&P 500 Index, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota.

Cephalon has a growing presence in Europe, the Middle East and Africa. The Cephalon European headquarters and pre-clinical development center are located in Maisons-Alfort, France, just outside of Paris. Key business units are located in England, Ireland, France, Germany, Italy, Spain, the Netherlands for the Benelux countries, and Poland for Eastern and Central European countries. Cephalon Europe markets more than 30 products in four areas: central nervous system, pain, primary care and oncology.

The company's proprietary products in the United States include: NUVIGIL, TREANDA® (bendamustine hydrochloride) for
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals
2. Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis
3. Cephalon Net Sales Increase 9% and Net Cash from Operations Surpasses $200 Million in the Third Quarter 2009
4. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
5. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
6. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
7. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
8. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
9. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
10. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
11. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... NEW YORK , Aug. 20, 2014 ... market research report is available in its ... (The Market for Bluetooth, RFID, Zigbee, UWB ... http://www.reportlinker.com/p0652514/Wireless-Opportunities-in-Healthcare-The-Market-for-Bluetooth-RFID-Zigbee-UWB-WWAN-WMAN-WLAN-and-other-technologies.html ... Market for Bluetooth, RFID, Zigbee, UWB WWAN, ...
(Date:8/20/2014)... Mass. , Aug. 20, 2014 /PRNewswire/ ... electrophysiology (EP) mapping and ablation device market ... use ablation to treat atrial fibrillation (AF). ... primary treatment option for AF will spur ... this application, such as advanced loop diagnostic ...
(Date:8/20/2014)... -- Reportlinker.com announces that a new market research report ... Hygiene Products Industry http://www.reportlinker.com/p01374691/Global-Feminine-Hygiene-Products-Industry.html ... Feminine Hygiene Products in US$ Million by the following ... The report provides separate comprehensive analytics for the US, ... , Europe , Asia-Pacific ...
Breaking Medicine Technology:Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 2Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 3Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 4Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 5Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 6Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 7Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 8Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 9Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 10Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 11Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 12Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 13Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 14Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 15Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 16Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3Global Feminine Hygiene Products Industry 2Global Feminine Hygiene Products Industry 3Global Feminine Hygiene Products Industry 4Global Feminine Hygiene Products Industry 5Global Feminine Hygiene Products Industry 6Global Feminine Hygiene Products Industry 7Global Feminine Hygiene Products Industry 8Global Feminine Hygiene Products Industry 9Global Feminine Hygiene Products Industry 10Global Feminine Hygiene Products Industry 11Global Feminine Hygiene Products Industry 12Global Feminine Hygiene Products Industry 13Global Feminine Hygiene Products Industry 14Global Feminine Hygiene Products Industry 15Global Feminine Hygiene Products Industry 16Global Feminine Hygiene Products Industry 17Global Feminine Hygiene Products Industry 18Global Feminine Hygiene Products Industry 19
... Nov. 5, 2010 Shrink Nanotechnologies, Inc. ("Shrink") ... innovative nanotechnology company developing products and licensing opportunities ... sensors and biotechnology research and development tools businesses, ... – the StemDisc450™, a high-yield, low cost, patent-pending ...
... 2010 Medivation, Inc. (Nasdaq: MDVN ) today ... the third quarter ended September 30, 2010. "In ... development program into earlier stage patients with the initiation of ... advanced prostate cancer who have not yet received chemotherapy.  Additionally, ...
Cached Medicine Technology:Shrink Nanotechnologies Unveils Videos of StemDisc450 Prototype Growing Human Embryonic Stem Cells 2Shrink Nanotechnologies Unveils Videos of StemDisc450 Prototype Growing Human Embryonic Stem Cells 3Shrink Nanotechnologies Unveils Videos of StemDisc450 Prototype Growing Human Embryonic Stem Cells 4Shrink Nanotechnologies Unveils Videos of StemDisc450 Prototype Growing Human Embryonic Stem Cells 5Medivation Reports Third Quarter 2010 Financial Results and Provides Corporate Update 2Medivation Reports Third Quarter 2010 Financial Results and Provides Corporate Update 3Medivation Reports Third Quarter 2010 Financial Results and Provides Corporate Update 4Medivation Reports Third Quarter 2010 Financial Results and Provides Corporate Update 5Medivation Reports Third Quarter 2010 Financial Results and Provides Corporate Update 6Medivation Reports Third Quarter 2010 Financial Results and Provides Corporate Update 7
(Date:8/20/2014)... 20, 2014 Understanding the impact ... physician stakeholders networks impacting the launch of new ... Canada, and Emerging Markets. , This Flash Report ... on stakeholder management needs for the melanoma market. ... targeted therapy investigational agents that are further improving ...
(Date:8/20/2014)... 2014 The award-winning plastic surgery group, ... its presence throughout Houston to a third office, located ... Laser Center building. ACPS plastic surgeon Dr. Rolando Morales ... ACPS, which has risen to become one of the ... the state since its establishment in 1996 by plastic ...
(Date:8/20/2014)... technique that underpins much of modern science, Chemical ... a special edition on X-ray crystallography its past, ... is the weekly news magazine of the American Chemical ... technique got its start when German physicist Max von ... a crystal in 1912. In the century following von ...
(Date:8/20/2014)... 2014 According to an order signed ... in the multicounty litigation (MCL) case pending in the ... HIP IMPLANTS LITIGATION; no. BER-L-3971-11), nearly 350 lawsuits against ... without prejudice. The cases enumerated in the order of ... The Rottenstein Law Group LLP, a national personal injury ...
(Date:8/20/2014)... 2014 It’s no secret that millions ... the National Institute on Drug Abuse, nearly 24 million ... even more alarming is the fact that the total ... , Those locked in a struggle with substance abuse ... But now, the newly-redesigned AbuseTreatmentCenters.net has released updated lists ...
Breaking Medicine News(10 mins):Health News:Download HeartBeat Experts White Paper: A Stakeholder Engagement Strategy is Critical for the Evolving Melanoma Treatment Setting 2Health News:Aesthetic Center for Plastic Surgery Expands Its Reach in Texas 2Health News:350 NJ DePuy ASR Lawsuits Dismissed Pending Settlement Talks, Notes Rottenstein Law Group LLP 2Health News:Re-Launched AbuseTreatmentCenters.net Offering New List of Substance Abuse Resources 2
... A research finds that the sea urchin's genome is remarkably ... to preventing and curing several human diseases. //University of Central ... study and published the results in the November issue of ... and spiny and have no eyes. The sea urchin has ...
... of cartilage in joints, is likely to be more ... led by David Felson, a professor at the Boston ... of the knee for 30 months. Twelve percent of ... of BBC News. ,The researchers found that ...
... Hopkins Children’s Center and elsewhere suggests that only one ... medicine to control dangerous flare-ups of the disease. ... researchers say, because preventive therapy failure leads to over-reliance ... and to more complications and increased risk of death. ...
... for depression. Even if you are under medical care and ... December issue of Mayo Clinic Women's HealthSource offers five self-care ... risk of recurrence. ,1. Keep active. As ... days has been shown to improve mood. Long-term regular exercise ...
... juvenile diabetics, it is not surprising that parents are a ... What used to be a malady of the middle aged ... that parents and doctors recognize the symptoms early, lest matters ... the International Diabetes Federation (IDF) corroborates this unhealthy trend of ...
... reason why teenage years are perceived as 'tumultuous'. When ... Box has opened. //Such teens are prone to misusing ... a recent insight indicates. ,The Canadian Centre on ... among 15- to 19-year-olds, drawing on the strength of ...
Cached Medicine News:Health News:Sea Urchin Genome Similar To Man And May Cure Diseases 2Health News:City Kids With Asthma Lose Out on Preventive Treatment 2Health News:Five Self-Care Strategies For Depression 2
0.12 mm, 1 x 2 teeth. Serrated handle with polished finish....
Stainless steel model of the popular Nordan titanium Colibri forceps. Tying platform with 0.12 mm teeth for grasping delicate structures. Flattened round handle with polished finish....
0.4 mm, 1 x 2 teeth 7 mm tying platform. Serrated handle with polished finish....
Solid lower plate with outside width 15 mm. Open serrated upper plate with inside dimensions 9 x 12 mm. Serrated handle with locking thumb screw and polished finish....
Medicine Products: